Literature DB >> 33128017

Molecular and cellular mechanisms of liver fibrosis and its regression.

Tatiana Kisseleva1, David Brenner2.   

Abstract

Chronic liver injury leads to liver inflammation and fibrosis, through which activated myofibroblasts in the liver secrete extracellular matrix proteins that generate the fibrous scar. The primary source of these myofibroblasts are the resident hepatic stellate cells. Clinical and experimental liver fibrosis regresses when the causative agent is removed, which is associated with the elimination of these activated myofibroblasts and resorption of the fibrous scar. Understanding the mechanisms of liver fibrosis regression could identify new therapeutic targets to treat liver fibrosis. This Review summarizes studies of the molecular mechanisms underlying the reversibility of liver fibrosis, including apoptosis and the inactivation of hepatic stellate cells, the crosstalk between the liver and the systems that orchestrate the recruitment of bone marrow-derived macrophages (and other inflammatory cells) driving fibrosis resolution, and the interactions between various cell types that lead to the intracellular signalling that induces fibrosis or its regression. We also discuss strategies to target hepatic myofibroblasts (for example, via apoptosis or inactivation) and the myeloid cells that degrade the matrix (for example, via their recruitment to fibrotic liver) to facilitate fibrosis resolution and liver regeneration.

Entities:  

Mesh:

Year:  2020        PMID: 33128017     DOI: 10.1038/s41575-020-00372-7

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  280 in total

Review 1.  Liver fibrosis -- from bench to bedside.

Authors:  Scott L Friedman
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers.

Authors:  A Schmitt-Gräff; S Krüger; F Bochard; G Gabbiani; H Denk
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

Review 3.  Hepatic stellate cells and the reversal of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  J Gastroenterol Hepatol       Date:  2006-10       Impact factor: 4.029

4.  Deactivation of hepatic stellate cells during liver fibrosis resolution in mice.

Authors:  Juliane S Troeger; Ingmar Mederacke; Geum-Youn Gwak; Dianne H Dapito; Xueru Mu; Christine C Hsu; Jean-Philippe Pradere; Richard A Friedman; Robert F Schwabe
Journal:  Gastroenterology       Date:  2012-06-27       Impact factor: 22.682

Review 5.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 6.  Epithelial-mesenchymal transition and its implications for fibrosis.

Authors:  Raghu Kalluri; Eric G Neilson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.

Authors:  J P Iredale; R C Benyon; J Pickering; M McCullen; M Northrop; S Pawley; C Hovell; M J Arthur
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

8.  Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection.

Authors:  Mei Lu; Jia Li; Talan Zhang; Loralee B Rupp; Sheri Trudeau; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Fujie Xu; Joseph A Boscarino; Mark A Schmidt; Vinutha Vijayadeva; Stuart C Gordon
Journal:  Clin Gastroenterol Hepatol       Date:  2016-01-22       Impact factor: 11.382

9.  Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis.

Authors:  Tatiana Kisseleva; Min Cong; Yonghan Paik; David Scholten; Chunyan Jiang; Chris Benner; Keiko Iwaisako; Thomas Moore-Morris; Brian Scott; Hidekazu Tsukamoto; Sylvia M Evans; Wolfgang Dillmann; Christopher K Glass; David A Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

Review 10.  Histopathological evaluation of liver fibrosis and cirrhosis regression.

Authors:  Regina C Lo; Haeryoung Kim
Journal:  Clin Mol Hepatol       Date:  2017-12-20
View more
  126 in total

Review 1.  Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.

Authors:  Arjuna Singanayagam; Evangelos Triantafyllou
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

2.  Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway.

Authors:  Ying Cao; Weili Mai; Rui Li; Shuwei Deng; Lan Li; Yanxi Zhou; Qiushi Qin; Yue Zhang; Xingang Zhou; Ming Han; Pu Liang; Yonghong Yan; Yu Hao; Wen Xie; Jie Yan; Liuluan Zhu
Journal:  Cell Mol Life Sci       Date:  2022-05-19       Impact factor: 9.261

3.  EP3 enhances adhesion and cytotoxicity of NK cells toward hepatic stellate cells in a murine liver fibrosis model.

Authors:  Xixi Tao; Rui Zhang; Ronglu Du; Tingting Yu; Hui Yang; Jiwen Li; Yuhong Wang; Qian Liu; Shengkai Zuo; Xi Wang; Michael Lazarus; Lu Zhou; Bangmao Wang; Ying Yu; Yujun Shen
Journal:  J Exp Med       Date:  2022-04-14       Impact factor: 14.307

4.  Antifibrogenic and apoptotic effects of Ocoxin in cultured rat hepatic stellate cells.

Authors:  Marina Ruiz de Galarreta; Elena Arriazu; María P Pérez de Obanos; Eduardo Ansorena; María J Iraburu
Journal:  J Physiol Biochem       Date:  2022-03-03       Impact factor: 4.158

5.  Modified Lipid Nanocapsules for Targeted Tanshinone IIA Delivery in Liver Fibrosis.

Authors:  Asmaa A Ashour; Amal H El-Kamel; Doaa A Abdelmonsif; Hoda M Khalifa; Alyaa A Ramadan
Journal:  Int J Nanomedicine       Date:  2021-12-08

6.  MCLR-elicited hepatic fibrosis and carcinogenic gene expression changes persist in rats with diet-induced nonalcoholic steatohepatitis through a 4-week recovery period.

Authors:  Tarana Arman; J Allen Baron; Katherine D Lynch; Laura A White; Johnny Aldan; John D Clarke
Journal:  Toxicology       Date:  2021-11-02       Impact factor: 4.221

7.  Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis.

Authors:  Mengzhen Kuang; Hao Wu; Lan Hu; Xinying Guo; Daochuan He; Bo Liu; Mengqian Chen; Jie Gu; Jianxin Gu; Xiaoqing Zeng; Yuanyuan Ruan
Journal:  Glycoconj J       Date:  2021-02-20       Impact factor: 2.916

8.  Salidroside Inhibits CCl4-Induced Liver Fibrosis in Mice by Reducing Activation and Migration of HSC Induced by Liver Sinusoidal Endothelial Cell-Derived Exosomal SphK1.

Authors:  Qiannan Ye; Yang Zhou; Changqing Zhao; Lieming Xu; Jian Ping
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

9.  Chronic Alcohol Exposure of Cells Using Controlled Alcohol-Releasing Capillaries.

Authors:  Wanil Kim; Hye-Seon Jeong; Sang-Chan Kim; Chang-Hyung Choi; Kyung-Ha Lee
Journal:  Cells       Date:  2021-05-06       Impact factor: 6.600

10.  A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels.

Authors:  Xiaoke Li; Yufeng Xing; Daqiao Zhou; Huanming Xiao; Zhenhua Zhou; Zhiyi Han; Xuehua Sun; Shuo Li; Ludan Zhang; Zhiguo Li; Peng Zhang; Jiaxin Zhang; Ningyi Zhang; Xu Cao; Xiaobin Zao; Hongbo Du; Guangdong Tong; Xiaoling Chi; Yueqiu Gao; Yong'an Ye
Journal:  Front Med (Lausanne)       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.